Clinical-Scale Cultures of Cord Blood CD34+ Cells to Amplify Committed Progenitors and Maintain Stem Cell Activity

We developed a clinical-scale cord blood (CB) cell ex vivo procedure to enable an extensive expansion of committed progenitors—colony-forming cells (CFCs) without impairing very primitive hematopoietic stem cells (HSCs). CD34++ cells, selected from previously cryopreserved and thawed CB units, were cultured in two steps (diluted 1:4 after 6 days) in the presence of stem cell factor (SCF), fms-related tyrosine kinase 3 ligand (Flt-3L), megakaryocyte growth and development factor (MGDF) (100 ng/ml each), granulocyte-colony stimulating factor (G-CSF) (10 ng/ml) in HP01 serum-free medium. HSC activity was evaluated in a serial transplantation assay, by detection of human cells (CD45, CD33, CD19 and CFC of human origin) in bone marrow (BM) of primary and secondary recipient NOD/SCID mice 6–8 weeks after transplantation. A wide amplification of total cells (~350-fold), CD34+ cells (~100-fold), and CFC (~130-fold) without impairing the HSC activity was obtained. The activity of a particular HSC subpopulation (SRCCFC) was even enhanced. Thus, an extensive ex vivo expansion of CFCs is feasible without impairing the activity of HSCs. This result was enabled by associating antioxidant power of medium with an appropriate cytokine cocktail (i.e., mimicking physiologic effects of a weak oxygenation in hematopoietic environment).

[1]  Colleen Delaney,et al.  Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution , 2010, Nature Medicine.

[2]  J. Boiron,et al.  [Ex vivo expansion of hematopoietic stem cells: concept and clinical benefit]. , 2009, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[3]  G. Dohr,et al.  Protocols for Hematopoietic Stem Cell Expansion from Umbilical Cord Blood , 2009, Cell transplantation.

[4]  P. Sanberg,et al.  Human Umbilical Cord Blood Cell Grafts for Brain Ischemia , 2009, Cell transplantation.

[5]  R. Sakthivel,et al.  Ex Vivo Nanofiber Expansion and Genetic Modification of Human Cord Blood-Derived Progenitor/Stem Cells Enhances Vasculogenesis , 2009, Cell transplantation.

[6]  I. Weissman,et al.  The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases. , 2008, Blood.

[7]  K. Kaushansky,et al.  Thrombopoietin (TPO) regulates HIF-1α levels through generation of mitochondrial reactive oxygen species , 2008, International journal of hematology.

[8]  A. Nagler,et al.  Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial , 2008, Bone Marrow Transplantation.

[9]  Y. Sugimoto,et al.  Ex Vivo Culture of Human Cord Blood Hematopoietic Stem/Progenitor Cells Adversely Influences Their Distribution to Other Bone Marrow Compartments After Intra‐Bone Marrow Transplantation , 2008, Stem cells.

[10]  Z. Pan,et al.  Ex Vivo Expansion and Transplantation of Hematopoietic Stem/Progenitor Cells Supported by Mesenchymal Stem Cells from Human Umbilical Cord Blood , 2007, Cell transplantation.

[11]  Chi-kong Li,et al.  Promoting Effects of Serotonin on Hematopoiesis: Ex Vivo Expansion of Cord Blood CD34+ Stem/Progenitor Cells, Proliferation of Bone Marrow Stromal Cells, and Antiapoptosis , 2007, Stem cells.

[12]  J. Reiffers,et al.  Large‐scale expansion and transplantation of CD34+ hematopoietic cells: in vitro and in vivo confirmation of neutropenia abrogation related to the expansion process without impairment of the long‐term engraftment capacity , 2006, Transfusion.

[13]  V. Praloran,et al.  Very Low O2 Concentration (0.1%) Favors G0 Return of Dividing CD34+ Cells , 2006, Stem cells.

[14]  I. Lamrissi‐Garcia,et al.  A clinical‐scale expansion of mobilized CD34+ hematopoietic stem and progenitor cells by use of a new serum‐free medium , 2006, Transfusion.

[15]  G. Vezon,et al.  Cord blood processing by using a standard manual technique and automated closed system "Sepax" (Kit CS-530). , 2005, Stem cells and development.

[16]  F. Lacombe,et al.  Simultaneous Maintenance of Human Cord Blood SCID‐Repopulating Cells and Expansion of Committed Progenitors at Low O2 Concentration (3%) , 2004, Stem cells.

[17]  Z. Ivanovic.  Interleukin-3 and ex vivo maintenance of hematopoietic stem cells: facts and controversies. , 2004, European cytokine network.

[18]  G. Vezon,et al.  An efficient large-scale thawing procedure for cord blood cells destined for selection and ex vivo expansion of CD34+ cells. , 2003, Journal of hematotherapy & stem cell research.

[19]  G. Vezon,et al.  Comparison of CD34+ cell collection on the CS‐3000+ and Amicus blood cell separators , 2003, Transfusion.

[20]  Pingfu Fu,et al.  Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell System. , 2003, Blood.

[21]  Chan Zeng,et al.  Transplantation of ex vivo expanded cord blood. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  E. Shpall,et al.  Ex vivo expanded cord blood cells provide rapid engraftment in fetal sheep but lack long-term engrafting potential. , 2002, Experimental hematology.

[23]  T. Fok,et al.  Preclinical ex vivo expansion of cord blood hematopoietic stem and progenitor cells: duration of culture; the media, serum supplements, and growth factors used; and engraftment in NOD/SCID mice , 2001, Transfusion.

[24]  F. Pflumio,et al.  In vitro and in vivo evidence for the long-term multilineage (myeloid, B, NK, and T) reconstitution capacity of ex vivo expanded human CD34(+) cord blood cells. , 2000, Experimental hematology.

[25]  D. Bryder,et al.  Interleukin-3 supports expansion of long-term multilineage repopulating activity after multiple stem cell divisions in vitro , 2000 .

[26]  P. Price,et al.  Prompt and durable engraftment in two older adult patients with high risk chronic myelogenous leukemia (CML) using ex vivo expanded and unmanipulated unrelated umbilical cord blood , 2000, Bone Marrow Transplantation.

[27]  S. Gluck,et al.  Ex vivo expansion of hematopoietic stem cells. , 1999, Journal of hematotherapy & stem cell research.

[28]  L. Qiu,et al.  Ex vivo expansion of CD34+ umbilical cord blood cells in a defined serum-free medium (QBSF-60) with early effect cytokines. , 1999, Journal of hematotherapy & stem cell research.

[29]  W. Piacibello,et al.  Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. , 1997, Blood.

[30]  D. Sutherland,et al.  The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. , 1996, Journal of hematotherapy.

[31]  Z. Ivanovic,et al.  Revue générale Expansion ex vivo des cellules hematopoiétiques : concept et utilité clinique Ex vivo expansion of hematopoietic stem cells : Concept and clinical benefit , 2009 .

[32]  I. Lamrissi‐Garcia,et al.  Human cell engraftment after busulfan or irradiation conditioning of NOD/SCID mice. , 2006, Haematologica.

[33]  M. Bhatia,et al.  Identification of growth factor conditions that reduce ex vivo cord blood progenitor expansion but do not alter human repopulating cell function in vivo. , 2005, Haematologica.

[34]  J. Dick,et al.  Distinct classes of human stem cells that differ in proliferative and self-renewal potential , 2001, Nature Immunology.